Prostaglandin E- major urinary metabolite (PGE-MUM) as a tumor marker for lung adenocarcinoma

2018 Fiscal Year Annual Research Report

• Project/Area Number: 16K09558
• Research Institution: Jikei University School of Medicine
• Principal Investigator: 内海 裕文 東京慈恵会医科大学, 医学部, 助教 (00773855)
• Co-Investigator(Kenkyū-buntansha): 原 弘道 東京慈恵会医科大学, 医学部, 講師 (70398791)
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: 尿中PGE-MUM / 肺腺癌

Outline of Annual Research Achievements

Prostaglandin E- major urinary metabolite (PGE-MUM) levels were significantly elevated in patients with lung adenocarcinoma. PGE-MUM level of 14.9 μg/g・Cr showed 70.4% sensitivity and 67.7% specificity for diagnosis of lung adenocarcinoma. PGE-MUM levels tended to be positively correlated with cancer progression determined by TNM staging system. Advanced stage (stageⅢ, stageⅣ,recurrence) was significantly associated with high PGE-MUM by logistic regression analysis. No apparent correlation was demonstrated between PGE-MUM and CEA levels. PGE-MUM can be a promising biomarker reflecting systemic tumor burden of lung adenocarcinoma.

尿中PGE 代謝産物（prostaglandin E-major urinary metabolite: PGE-MUM）は肺腺癌患者で増加していた。PGE-MUMは14.9 g/g・Crをカットオフとすると肺腺癌の診断感度70.4％、特異度67.7％であった。PGE-MUMは肺癌の進展ともに増加する傾向であった。肺癌が進行期であることは有意にPGE-MUM高値と関連した。PGE-MUMとCEAは相関がみられなかった。PGE-MUMは肺腺癌の腫瘍量を反映する新たなバイオマーカーとなる可能性がある。